Clinical Trials

Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.

 

Health Service Research Trials

 

  • STUDY15667

    Implementation and Effectiveness Trial of HN STAR

    This trial studies how a computer program, the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR) works in helping health care providers care for survivors of head and neck squamous cell cancer. HN-STAR is a type of survivorship tool that survivors and their health care providers may use together to better manage the survivors' health.

    Study Information



  • STUDY17603

    Optimizing Tobacco Treatment Delivery for People Living with HIV

    To conduct a randomized clinical trial with PLWH who smoke (N=230) comparing smoking cessation outcomes consistent with the RFA including: biochemically verified 7-day point prevalence abstinence (PPA) rates, continuous abstinence (Weeks 9-12), and the number of 24-hour quit attempts at the end of study treatment (Week 12) between participants who receive TAU and PrOMOTE.

    Study Information



  • STUDY22933

    A Stepped Wedge Cluster Randomized Trial Comparing a Navigation Based Multilevel Intervention With Treatment as Usual to Improve Initiation of Timely Postoperative Radiation Therapy in Adults with Locally Advanced Head and Neck Squamous Cell Carcinoma (The ENDURE Trial)

    Primary Objective: 1. To evaluate the effectiveness of ENDURE compared with TAU on the initiation of timely, guideline-adherent PORT among patients with LAHNSCC undergoing surgical therapy with a pathologic indication for PORT as measured by the proportion of patients who initiate PORT within 6 weeks of surgery. Secondary Objectives: 1. To evaluate the effectiveness of ENDURE compared with TAU on the timely initiation of PORT among patients with LAHNSCC undergoing surgical therapy with a pathologic indication for PORT as determined by (1) median time-to-PORT initiation following surgery and (2) treatment package time. 2. To assess the effectiveness of ENDURE compared with TAU on racial disparities in the timely initiation of PORT among Black and White patients with LAHNSCC undergoing surgical therapy with a pathologic indication for PORT as determined by (1) the proportion of patients who initiate PORT within 6 weeks of surgery; (2) median time-to-PORT initiation following surgery; and (3) treatment package time. 3. To evaluate the effect of ENDURE compared with TAU on resolving barriers to timely PORT. 4. To compare the effect of ENDURE compared with TAU on satisfaction with cancer care as determined by Patient Satisfaction with Cancer Care scores. 5. To examine the mechanism through which ENDURE reduces treatment delays compared with TAU as measured by key (1) processes of cancer care delivery and (2) health behavior constructs at the patient and team levels. 6. To characterize the implementation outcomes related to fidelity, adaptation, acceptability, appropriateness, and feasibility of ENDURE across diverse care delivery settings. Primary Endpoint: PORT delay, defined per National Comprehensive Cancer Network (NCCN) Guidelines as the initiation of PORT > 6 weeks (42 days) following definitive surgery for HNSCC. Select Secondary Endpoints: Time-to-PORT initiation, defined as the number of days from the date of definitive surgery for HNSCC to the date of initiation of PORT. Treatment package time, defined as the number of days from the date of definitive surgery for HNSCC to the date of PORT completion. Patient Satisfaction with Cancer Care score. Pre-surgical radiation consultation, defined as the attendance by the patient at a consultation with the treating radiation oncologist prior to surgery to discuss radiation therapy in the definitive or adjuvant setting. Pre-radiation therapy dental extractions, defined as the extraction of indicated carious/non-restorable teeth prior to or during definitive surgery. Time from surgery to PORT referral, defined as the time, in days, from the date of the definitive surgical procedure to the date the referral (or postoperative appointment) is placed to discuss adjuvant therapy with the treating radiation oncologist. Time from PORT referral to appointment, defined as the time, in days, from the date of the definitive surgical procedure to the date that the patient attends a postoperative appointment with radiation oncology.

    Study Information



  • STUDY23695

    The Impact of Cannabis and Tobacco/Nicotine Product Co Use in Young Adults: Prospective Cessation Evaluation and Substitution

    Aim 1: Substitutability and Nicotine Treatment Outcomes. Evaluate the impact of behavioral economically derived measures of substance substitutability on Week 12 end of treatment (EOT) nicotine abstinence. Hypothesis 1: Participants with greater substitutability patterns will have lower rates of 7-day point prevalence abstinence from nicotine at EOT compared to patterns indicating a complementary relationship. Aim 2: Cannabis Demand and Use During Nicotine Treatment. Determine if treatment-induced nicotine abstinence, reduction or withdrawal is (a) associated with co-occurring changes in cannabis demand and use and (b) if substitutability modifies this relationship. Hypothesis 2: Nicotine use/withdrawal and associated changes in cannabis use and demand will be moderated by time varying changes in substitutability. Aim 3: Nicotine and Cannabis Use Changes During Treatment. Assess the reciprocal prospective relationship between nicotine and cannabis use (including reduction and abstinence) during nicotine treatment. Hypothesis 3: Cross-lagged changes in nicotine and cannabis use during treatment will have a positive correlation; i.e., increased cannabis use in the prior week will be associated with increased current nicotine use.

    Study Information



  • STUDY23828

    Replacing Invasive Cystoscopy with Urine Testing for Non muscle Invasive Bladder Cancer Surveillance

    To determine whether urinary quality of life after surveillance is significantly improved in the urine testing arms

    Study Information